{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-394492","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-09-17T21:05:24+00:00","discovered_at":"2026-09-17T21:06:03.781996+00:00","generated_at":"2026-09-17T21:06:21.289009+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Tempest secures exclusive option to license Senlang's CD7-targeted in vivo CAR-T platform","bullets":["Option exercisable within 4 months for ~$447,000 fee; exclusive license for ex-Greater China rights.","Post-exercise fees: annual maintenance $10M-$14M over first 3 years, 6% net-sales royalty, sublicense revenue share.","Lead BCMA/GPRC5D dual-targeting candidate in Phase 1 for relapsed/refractory multiple myeloma; early in vivo CAR-T generation observed.","As of Aug 25, 2026, no Grade 3+ CRS or ICANS; safety profile supports continued dose escalation.","Agreement complements Tempest's existing LNP platform; expands portfolio to hematologic and autoimmune indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-394492","json":"https://secwatch.observer/filing/0001193125-26-394492.json","markdown":"https://secwatch.observer/filing/0001193125-26-394492.md","text":"https://secwatch.observer/filing/0001193125-26-394492.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526394492/0001193125-26-394492-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526394492/d185404d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-17T21:06:21.289009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}